Virtual Library

Start Your Search

P. Sun



Author of

  • +

    Poster Session (ID 8)

    • Event: ACLC 2018
    • Type: Poster Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
    • +

      P075 - Hippo-YAP Pathway Mediated Resistance to Crizotinib in ROS1-Positive Lung Cancer (ID 113)

      00:00 - 00:00  |  Author(s): P. Sun

      • Abstract

      Background:
      At present, limited data exist on the spectrum of resistance mechanisms in ROS1-positive lung cancer. The Hippo-YAP pathway has been recently implicated in the acquisition of drug resistance in anti-cancer therapy, Yes-associated protein (YAP) is a main mediator of the Hippo pathway, but no data are available about Hippo-YAP pathway in ROS1-positive lung cancer. In this study, we evaluated the expression of YAP in non-small-cell lung carcinoma (NSCLC) tissues, we also investigated the role of YAP in primary and crizotinib-resistant cell lines.


      Method:
      Immunohistochemical (IHC) staining of YAP and epithelial-to-mesenchymal transition (EMT) proteins was performed on tissue sections from 200 NSCLCs. Correlations between the expression of the above proteins and clinicopathologic features and prognostic significance were analyzed. Crizotinib -resistant cells (HCC78CR) were established using crizotinib -na